<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81705">
  <stage>Registered</stage>
  <submitdate>22/11/2006</submitdate>
  <approvaldate>23/11/2006</approvaldate>
  <actrnumber>ACTRN12606000485538</actrnumber>
  <trial_identification>
    <studytitle>A randomised controlled trial to evaluate the effectiveness of Ganoderma lucidum for treatment of hyperglycemia in persons with metabolic syndrome</studytitle>
    <scientifictitle>A randomised controlled trial to evaluate the effectiveness of Ganoderma lucidum for treatment of hyperglycemia in persons with metabolic syndrome</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metabolic syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Normal metabolism and endocrine development and function</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Comparison Arm 1. Ganoderma lucidum spore and extract (imported by Alllife Pty Ltd) 4.2g per day taken as oral capsules for 16 weeks
Comparison Arm 2. Ganoderma lucidum (3g) with Cordyceps sinensis extract (1.2g) (imported by Alllife Pty Ltd) total 4.2g per day taken as oral capsules for 16 weeks</interventions>
    <comparator>Control Arm 3. Control intervention of placebo of matched excipient ingredients as oral capsules taken for 16 weeks</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Fasting plasma glucose</outcome>
      <timepoint>Measured at baseline, 8 weeks, 16 weeks and follow-up at 24 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>HbA1C (glycosylated haemoglobin)</outcome>
      <timepoint>Measured at baseline, 8 weeks, 16 weeks and follow-up at 24 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Blood pressure</outcome>
      <timepoint>Measured at baseline, 8 weeks, 16 weeks and follow-up at 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood triglycerides</outcome>
      <timepoint>Measured at baseline, 8 weeks, 16 weeks and follow-up at 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood high density lipoproteins</outcome>
      <timepoint>Measured at baseline, 8 weeks, 16 weeks and follow-up at 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Obesity</outcome>
      <timepoint>Measured at baseline, 8 weeks, 16 weeks and follow-up at 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health related Quality of Life (SF-36)</outcome>
      <timepoint>Measured at baseline, 8 weeks, 16 weeks and follow-up at 24 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Must have hyperglycemia (FPG- Fasting Plasma Glucose over 6.1 mmol/L) and meet National Cholesterol Education Program- Adult Treatment Panel III criteria for metabolic syndrome.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Unstable health (recent or immediate future hospitalisation, surgery), recent history of hypoglycemic episodes, use insulin, history or organ transplant, liver or kidney disease, infection, pregnancy and allergy to mushrooms.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Numbered containers</concealment>
    <sequence>Simple randomisation computerised sequence generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>In this study the subjects, therapists, assessors and data analysts will all be blinded. The randomisation schedule will be released by the external randomisation officer after data analysis and preliminary write up is complete.</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>29/01/2007</anticipatedstartdate>
    <actualstartdate>25/01/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate>16/05/2008</actualenddate>
    <samplesize>168</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Allife Pty Ltd</primarysponsorname>
    <primarysponsoraddress>12 Giffard Street, Silverwater NSW 2128 Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Western Sydney, Centre for Complementary Medicine Research</fundingname>
      <fundingaddress>Centre for Complementary Medicine Research, Blg 5, Campbelltown Campus, University of Western Sydney, Locked Bag 1797, Penrith, NSW 2751, Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other</sponsortype>
      <sponsorname>Cardiac Health Institute</sponsorname>
      <sponsoraddress>173 Shaftsbury Road, Eastwood, 2122, NSW, Australia</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Metabolic syndrome is a cluster of cardiovascular risk factors such as diabetes, hypertension, obesity, and abnormal cholesterol and blood fat levels. At present there is no single pharmaceutical agent which can effectively treat metabolic syndrome, but rather, multiple medications are given for each risk factor. In China, two mushrooms- Ganoderma lucidum and Cordyceps sinensis, have been used for these conditions and animal, in-vitro and small human studies indicate positive effects against the multiple components of metabolic syndrome. This study will be the first randomised clinical trial of this intervention for the efficacy and treatment of metabolic syndrome.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>UWS Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>05/118</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Biosafety Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>BRSC 05/18</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Director of Cardiac Health Institute</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Ms</title>
      <name>Nerida Klupp</name>
      <address>Room 5.02, Blg 24
Campbelltown Campus
University of Western Sydney
Locked Bag 1797
Penrith South DC 
NSW 1797</address>
      <phone>02 4620 3759</phone>
      <fax>02 4620 3792</fax>
      <email>n.klupp@uws.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Nerida Klupp</name>
      <address>Room 5.02, Blg 24
Campbelltown Campus
University of Western Sydney
Locked Bag 1797
Penrith South DC 
NSW 1797</address>
      <phone>02 4620 3759</phone>
      <fax>02 4620 3792</fax>
      <email>n.klupp@uws.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Nerida Klupp</name>
      <address>Centre for Complementary Medicine Research, Blg 5, Campbelltown Campus, University of Western Sydney, Locked Bag 1797, Penrith, NSW 2751, Australia</address>
      <phone>+61 2 46203759</phone>
      <fax />
      <email>n.klupp@uws.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>